ALDX Stock Crashes 71% After FDA Rejects Lead Dry Eye Drug; Class Action Lawsuit Filed

Aldeyra Therapeutics Inc. ($ALDX) has become the subject of a class action lawsuit filed by Pomerantz Law Firm following a devastating FDA rejection of its flagship drug candidate, reproxalap, which was designed to treat dry eye disease. The regulatory setback triggered a catastrophic stock decline of 70.69%, sending shares plummeting to $1.24 per share on March 17, 2026. The lawsuit represents a significant blow to shareholders who have suffered substantial losses, with investors having until May 29, 2026 to join the legal action against the biopharmaceutical company.

The collapse underscores the inherent risks of clinical-stage drug development and raises questions about the company's regulatory strategy and trial design preceding the FDA's decision. For investors holding $ALDX shares, the situation represents both a potential vehicle for recourse through litigation and a critical moment to assess exposure to an increasingly distressed biotech firm.

The FDA's Rejection and Drug Development Failure

The FDA's rejection of reproxalap represents a total loss of the company's most advanced pipeline asset and the culmination of years of development efforts. According to regulatory correspondence, the FDA cited two primary concerns:

• Lack of substantial evidence of efficacy: The agency determined that reproxalap did not demonstrate sufficient clinical benefit to warrant approval for dry eye disease treatment
• Inconsistent study results: Clinical trial data showed variability across studies, preventing the FDA from establishing a reliable safety and efficacy profile

These deficiencies are particularly damaging because they suggest fundamental problems with either the drug's mechanism of action, trial design, or patient population selection—issues that typically cannot be easily remedied through additional studies.

For Aldeyra Therapeutics, reproxalap represented the company's lead program and primary catalyst for clinical advancement. The drug's failure eliminates the most probable near-term revenue opportunity and raises questions about the viability of the company's pipeline strategy. The firm's development efforts now face significant uncertainty, with investors forced to reassess the probability of success for any remaining candidates.

Market Context: Dry Eye Disease and Competitive Landscape

The dry eye disease (DED) market represents a substantial therapeutic opportunity with significant unmet medical needs. The condition affects millions globally and has attracted considerable pharmaceutical industry attention, resulting in a increasingly competitive treatment landscape.

Industry Opportunity and Competitive Dynamics

The dry eye space has seen multiple recent approvals and pipeline advances:

• Market size: Dry eye disease represents a multi-billion dollar addressable market
• Recent competitors: Other firms have successfully developed and commercialized DED treatments, establishing established market presence
• Unmet needs: Despite existing therapies, significant patient populations remain inadequately treated, supporting continued development efforts

The FDA's rejection of reproxalap suggests that Aldeyra's approach to treating DED did not meet the regulatory standard for approval, potentially indicating that the company's mechanism of action or clinical approach was less compelling than competing development strategies in the space.

This outcome also reflects broader trends in biotech equity markets, where clinical failures in once-promising programs can trigger severe valuation compressions. The 71% decline in $ALDX demonstrates investor confidence in the company was substantially dependent upon reproxalap's approval prospects.

Investor Implications: Legal Recourse and Stock Valuation

Class Action Lawsuit and Recovery Potential

The Pomerantz Law Firm's class action lawsuit alleges that shareholders have suffered damages due to what may constitute securities law violations. Key implications for shareholders include:

• Lawsuit deadline: Investors have until May 29, 2026 to opt into the litigation
• Potential recoveries: Successful class action outcomes can result in monetary damages to shareholders, though recovery amounts and timing vary significantly
• Legal strategy: The lawsuit likely alleges that company management failed to disclose material information regarding trial safety, efficacy, or FDA feedback prior to the March 2026 announcement

Investors seeking to join the lawsuit should document their purchase dates, quantities, and prices, as these details establish damages calculations in class action settlements.

Implications for Stock Valuation and Company Viability

The $1.24 per share valuation reflects dramatic market repricing of Aldeyra's enterprise value. Key considerations for investors:

• Balance sheet impact: The company's cash position and runway become critical concerns without reproxalap revenue prospects
• Pipeline assessment: Remaining candidates face elevated scrutiny regarding development feasibility and market opportunity
• Acquisition risk: Distressed biotech firms often become acquisition targets; share price recovery may depend on M&A activity or strategic pivots
• Dilution concerns: Capital-constrained companies may pursue equity financing, diluting existing shareholders

The severe valuation compression suggests the market assigns minimal probability to near-term value creation from $ALDX's remaining operations or pipeline assets. Investors should assess whether the company possesses sufficient cash reserves to fund ongoing operations and whether management has articulated credible alternatives to the failed reproxalap program.

Forward Outlook and Strategic Implications

The rejection of reproxalap and subsequent class action filing establish a critical inflection point for Aldeyra Therapeutics. The company faces several potential paths forward:

1. Restructuring and pipeline optimization: Management may prioritize cost reduction and focus resources on highest-probability development programs
2. Strategic alternatives: Asset sales, partnerships, or acquisition may represent realistic outcomes for distressed equity holders
3. Clinical appeals: Highly unlikely given FDA's explicit concerns, but companies occasionally pursue post-rejection discussions

For broader biotech investors, the $ALDX situation reinforces several enduring lessons: clinical development carries irreducible risk; regulatory feedback during development must be carefully monitored; and investor confidence in small-cap biotech is fragile and subject to rapid reversal upon negative outcomes.

Shareholders who believe the company's disclosure practices or management's handling of the regulatory process violated securities laws should contact Pomerantz Law Firm to discuss potential membership in the class action. The May 29, 2026 deadline represents a critical window for preserving legal rights to pursue damages recovery.